THQM Stock Overview
Tchaikapharma High Quality Medicines AD engages in the development and manufacture of generic and in-licensed medicines in Bulgaria.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Tchaikapharma High Quality Medicines AD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | лв17.00 |
| 52 Week High | лв17.20 |
| 52 Week Low | лв14.94 |
| Beta | 0.065 |
| 1 Month Change | 0.59% |
| 3 Month Change | 1.19% |
| 1 Year Change | 13.07% |
| 3 Year Change | 35.34% |
| 5 Year Change | 144.54% |
| Change since IPO | 614.45% |
Recent News & Updates
Shareholder Returns
| THQM | BG Pharmaceuticals | BG Market | |
|---|---|---|---|
| 7D | 0% | -1.1% | -0.8% |
| 1Y | 13.1% | 3.5% | 11.4% |
Return vs Industry: THQM exceeded the BG Pharmaceuticals industry which returned 3.5% over the past year.
Return vs Market: THQM exceeded the BG Market which returned 11.4% over the past year.
Price Volatility
| THQM volatility | |
|---|---|
| THQM Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in BG Market | 6.7% |
| 10% least volatile stocks in BG Market | 2.1% |
Stable Share Price: Insufficient data to determine THQM's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine THQM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 189 | n/a | https://www.tchaikapharma.com |
Tchaikapharma High Quality Medicines AD engages in the development and manufacture of generic and in-licensed medicines in Bulgaria. The company offers anaesthetic, anti-inflammatory and anti-rheumatic, antibiotic, cardiovascular system, digestive system, diabetes and metabolism, nervous system, OTC, respiratory system, oncology, and other medicines. It also provides nutritional supplements.
Tchaikapharma High Quality Medicines AD Fundamentals Summary
| THQM fundamental statistics | |
|---|---|
| Market Cap | лв1.51b |
| Earnings (TTM) | лв4.18m |
| Revenue (TTM) | лв49.46m |
361.4x
P/E Ratio30.5x
P/S RatioIs THQM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| THQM income statement (TTM) | |
|---|---|
| Revenue | лв49.46m |
| Cost of Revenue | лв5.47m |
| Gross Profit | лв44.00m |
| Other Expenses | лв39.82m |
| Earnings | лв4.18m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.047 |
| Gross Margin | 88.95% |
| Net Profit Margin | 8.44% |
| Debt/Equity Ratio | 9.2% |
How did THQM perform over the long term?
See historical performance and comparison